Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.54 |
| ▸ | GABRP | O00591 | 2/20 | 0.41 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.41 |
| ▸ | GABRE | P78334 | 2/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.41 |
| ▸ | MAP2K3 | P46734 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15275826 | 0.83 | GRM5 (0.54) | GRM5MAP2K3NOS3NOS2IKBKB | |
| SCHEMBL11908134 | 0.81 | CCR1 (0.52) | GRM5MAP2K3NOS3NOS2RAB9A | |
| SCHEMBL11906527 | 0.79 | DHODH (0.40) | GRM5MAP2K3 | |
| SCHEMBL11908013 | 0.79 | MAP2K3 (0.40) | GRM5GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL262928 | 0.79 | GRM5 (0.54) | GRM5MAPTALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL28416653 | 0.79 | GRM5 (0.50) | GRM5MAP2K3NOS3NOS2MAPT | |
| SCHEMBL7462617 | 0.79 | MAP4K1 (0.50) | GRM5MAP2K3MAPTALDH1A1IKBKB | |
| SCHEMBL30775059 | 0.79 | GRM5 (0.54) | GRM5MAPTALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL7460660 | 0.79 | GRM5 (0.62) | GRM5ALDH1A1IKBKBLIMK1PIN1 | |
| SCHEMBL2373944 | 0.78 | ALDH1A1 (0.41) | GRM5GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | claimed |
| WO-2025264954-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250270213-A1 | PI3Ka INHIBITORS | PIKAVATION THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| CN-119654321-A | PI3K alpha inhibitors | 突触活化疗法股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-4511373-A1 | PI3K? INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2024163752-A1 | HETEROCYCLIC COMPOUNDS AS PI3Kα INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | WO | disclosed |
| WO-2024151759-A1 | HETEROCYCLIC COMPOUNDS AS PI3Kα INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2023205680-A1 | PI3Kα INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-3354640-A2 | MIF INHIBITORS AND THEIR USES | Innovimmune Biotherapeutics, Inc. (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2696682-B1 | MIF INHIBITORS AND THEIR USES | INNOVIMMUNE BIOTHERAPEUTICS INC (US) | 2018-03-21 | — | — | EP | disclosed |
| CN-101379036-A | Anthranilamide/2-amino-heteroarene carboxamide derivatives | HOFFMANN LA ROCHE (CH) | 2009-03-04 | — | — | CN | disclosed |
| US-20080269256-A1 | PYRIDINE-2-CARBOXYAMIDE DERIVATIVES | JAESCHKE GEORG | 2008-10-30 | — | — | US | disclosed |
| EP-1984340-A1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| US-7414060-B2 | Pyridine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| CN-101133027-A | Pyridine-2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | CN | disclosed |
| EP-1858854-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2007-11-28 | — | — | EP | disclosed |
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. | 2007-09-20 | — | — | US | disclosed |
| WO-2007090752-A1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| WO-2006094639-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | HOFFMANN-LA ROCHE INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269256-A1 | PYRIDINE-2-CARBOXYAMIDE DERIVATIVES | CNR2, CNR1, CHRNA2 | GRM5 169/4885GABRP 519/4885GABRD 1462/4885 |
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | AADAT, AAAS, AADAC | GRM5 1690/4885GABRP 716/4885GABRD 1296/4885 |
| US-20250270213-A1 | PI3Ka INHIBITORS | PIK3CA, PIK3C2A, PIK3R5 | GRM5 2876/4885GABRP 948/4885GABRD 3003/4885 |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | GRM3, GRM2, GRM1 | GRM5 18/4885GABRP 94/4885GABRD 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.